Cancer expert doubts claims about prostate cancer trialBMJ 2008; 337 doi: https://doi.org/10.1136/bmj.a979 (Published 24 July 2008) Cite this as: BMJ 2008;337:a979
- Andrew Cole
A leading clinical oncologist has raised questions about claims that a new drug could treat as many as 80% of men diagnosed as having the most aggressive and previously drug resistant form of prostate cancer.
The results of the phase I clinical trial by the Institute of Cancer Research and the Royal Marsden Hospital, showed significant tumour shrinkage and big falls in prostate specific antigen (PSA) concentrations in most of the 21 men with advanced prostate cancer who received the drug abiraterone acetate (Journal of Clinical Oncology 2008 Jul 21; doi: 10.1200/JCO.2007.15.9749).
But Nick James, professor of clinical oncology at Birmingham University, said that it was far …
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.